首页 > 最新文献

Technology in Cancer Research & Treatment最新文献

英文 中文
Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study. 术后原发区放疗对新发转移性乳腺癌生存率的影响:一项回顾性研究。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-05-07 DOI: 10.1177/15330338251341195
Pingchuan Li, Lineng Wei, Yinan Ji, Huawei Yang

IntroductionThe role of radiotherapy (RT) in de novo metastatic breast cancer (dnMBC) patients undergoing surgery remains controversial due to limited evidence. This study aimed to evaluate the impact of postoperative radiotherapy on survival outcomes in this population.Materials and methodsWe retrospectively analyzed 102 dnMBC patients who underwent surgery at a provincial cancer hospital. Patients were grouped based on whether they received postoperative RT. Baseline characteristics were compared using the chi-square test. Kaplan-Meier analysis and Cox proportional hazards models were used to assess the prognostic impact of postoperative radiotherapy on local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS).ResultsKM survival analysis showed that postoperative RT significantly improved LRFS (HR = 0.3634, 95%CI 0.1552-0.8508, p = .0197) and PFS (HR = 0.4903, 95%CI 0.3061-0.7855, p = .003) but had no significant effect on OS (HR = 0.7337, 95%CI 0.3514-1.508, p = .5395). Multivariate analysis identified postoperative RT as an independent protective factor for LRFS (HR = 0.265, 95%CI 0.088-0.795, p = .018) and PFS (HR = 0.525, 95%CI 0.313-0.882, p = .015). Subgroup analysis showed that for LRFS, RT had no significant interaction with different subgroup classification variables (all interaction p > .05). However, RT had a significant interaction with N stage for PFS (p = .016), specifically in N1-3 patients (HR = 0.384, 95% CI 0.221-0.668).ConclusionRT may improve disease control in selected dnMBC patients undergoing surgery, particularly those with lymph node metastasis. However, these findings still require further validation in larger, multicenter cohorts.

由于证据有限,放疗(RT)在接受手术的新发转移性乳腺癌(dnMBC)患者中的作用仍然存在争议。本研究旨在评估术后放疗对该人群生存结果的影响。材料与方法回顾性分析102例在省级肿瘤医院接受手术治疗的dnMBC患者。患者根据是否接受术后放疗进行分组。基线特征采用卡方检验进行比较。采用Kaplan-Meier分析和Cox比例风险模型评估术后放疗对局部无复发生存期(LRFS)、无进展生存期(PFS)和总生存期(OS)的预后影响。结果skm生存分析显示,术后放疗显著改善了LRFS (HR = 0.3634, 95%CI 0.1552 ~ 0.8508, p = 0.0197)和PFS (HR = 0.4903, 95%CI 0.3061 ~ 0.7855, p = 0.003),但对OS无显著影响(HR = 0.7337, 95%CI 0.3514 ~ 1.508, p = 0.5395)。多因素分析发现,术后放疗是LRFS (HR = 0.265, 95%CI 0.088-0.795, p = 0.018)和PFS (HR = 0.525, 95%CI 0.313-0.882, p = 0.015)的独立保护因素。亚组分析显示,对于LRFS, RT与不同亚组分类变量无显著交互作用(均交互作用p < 0.05)。然而,RT与PFS的N期有显著的相互作用(p = 0.016),特别是在N1-3患者(HR = 0.384, 95% CI 0.221-0.668)。结论放疗可改善部分手术患者的病情控制,尤其是有淋巴结转移的患者。然而,这些发现仍需要在更大的多中心队列中进一步验证。
{"title":"Survival Impact of Postoperative Primary Area Radiotherapy on De Novo Metastatic Breast Cancer: A Retrospective Study.","authors":"Pingchuan Li, Lineng Wei, Yinan Ji, Huawei Yang","doi":"10.1177/15330338251341195","DOIUrl":"10.1177/15330338251341195","url":null,"abstract":"<p><p>IntroductionThe role of radiotherapy (RT) in de novo metastatic breast cancer (dnMBC) patients undergoing surgery remains controversial due to limited evidence. This study aimed to evaluate the impact of postoperative radiotherapy on survival outcomes in this population.Materials and methodsWe retrospectively analyzed 102 dnMBC patients who underwent surgery at a provincial cancer hospital. Patients were grouped based on whether they received postoperative RT. Baseline characteristics were compared using the chi-square test. Kaplan-Meier analysis and Cox proportional hazards models were used to assess the prognostic impact of postoperative radiotherapy on local recurrence-free survival (LRFS), progression-free survival (PFS), and overall survival (OS).ResultsKM survival analysis showed that postoperative RT significantly improved LRFS (HR = 0.3634, 95%CI 0.1552-0.8508, <i>p</i> = .0197) and PFS (HR = 0.4903, 95%CI 0.3061-0.7855, <i>p</i> = .003) but had no significant effect on OS (HR = 0.7337, 95%CI 0.3514-1.508, <i>p</i> = .5395). Multivariate analysis identified postoperative RT as an independent protective factor for LRFS (HR = 0.265, 95%CI 0.088-0.795, <i>p</i> = .018) and PFS (HR = 0.525, 95%CI 0.313-0.882, <i>p</i> = .015). Subgroup analysis showed that for LRFS, RT had no significant interaction with different subgroup classification variables (all interaction <i>p</i> > .05). However, RT had a significant interaction with N stage for PFS (<i>p</i> = .016), specifically in N1-3 patients (HR = 0.384, 95% CI 0.221-0.668).ConclusionRT may improve disease control in selected dnMBC patients undergoing surgery, particularly those with lymph node metastasis. However, these findings still require further validation in larger, multicenter cohorts.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251341195"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12062640/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144000293","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study). PRaG治疗老年晚期恶性肿瘤患者的疗效和安全性:一项前瞻性、多中心临床研究方案(PRaG 9.0研究)。
IF 2.8 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-11-27 DOI: 10.1177/15330338251400412
Xiangrong Zhao, MengMeng Yang, Junjun Zhang, Yuehong Kong, Meiling Xu, Rongzheng Chen, Qian Yin, Sumeng Wang, Guangqiang Chen, Pengfei Xing, Liyuan Zhang

Background: Current evidence from evidence-based medicine is limited regarding the efficacy and safety of immunotherapy in elderly patients aged 75 years and older with malignant solid tumors. PRaG therapy, which combines PD-1/PD-L1 inhibitors, radiotherapy, and granulocyte-macrophage colony-stimulating factor (GM-CSF), aims to treat patients with advanced, refractory tumors. Preliminary findings indicate that patients aged 75 years and older can benefit from this treatment and can tolerate it well. Objective: This study aims to evaluate the efficacy and safety of the PRaG regimen in elderly patients with advanced malignant solid tumors to provide evidence-based support for immunotherapy in this population. Methods and Analysis: This study involves a multicenter, prospective, single-arm phase II clinical trial designed to enroll 29 patients aged 75 years and older with either newly diagnosed or recurrent metastatic advanced solid tumors that are histologically confirmed. All of the eligible patients will have had to receive at least two cycles of PRaG therapy until disease progression or intolerable adverse effects occurred. The study protocol was approved on September 12, 2023, by the Ethics Committee of the Second Affiliated Hospital of Soochow University (JD-LK-2023-082-I01) and by the ethics committees of all of the participating centers (Trial Registration Number: NCT06112041).

背景:目前来自循证医学的关于免疫治疗对75岁及以上高龄恶性实体瘤患者的有效性和安全性的证据有限。PRaG疗法结合了PD-1/PD-L1抑制剂、放疗和粒细胞-巨噬细胞集落刺激因子(GM-CSF),旨在治疗晚期难治性肿瘤患者。初步研究结果表明,75岁及以上的患者可以从这种治疗中受益,并能很好地耐受。目的:本研究旨在评价PRaG方案在老年晚期恶性实体瘤患者中的疗效和安全性,为该人群的免疫治疗提供循证支持。方法和分析:本研究涉及一项多中心、前瞻性、单臂II期临床试验,招募29例年龄在75岁及以上的患者,这些患者要么是新诊断的,要么是组织学证实的复发转移性晚期实体瘤。所有符合条件的患者将不得不接受至少两个周期的PRaG治疗,直到疾病进展或无法忍受的不良反应发生。研究方案于2023年9月12日由苏州大学第二附属医院伦理委员会(JD-LK-2023-082-I01)和所有参与中心伦理委员会(试验注册号:NCT06112041)批准。
{"title":"Efficacy and Safety of PRaG Therapy in Elderly Patients with Advanced Malignant Tumors: A Prospective, Multicenter Clinical Study Protocol (PRaG 9.0 Study).","authors":"Xiangrong Zhao, MengMeng Yang, Junjun Zhang, Yuehong Kong, Meiling Xu, Rongzheng Chen, Qian Yin, Sumeng Wang, Guangqiang Chen, Pengfei Xing, Liyuan Zhang","doi":"10.1177/15330338251400412","DOIUrl":"10.1177/15330338251400412","url":null,"abstract":"<p><p><b>Background:</b> Current evidence from evidence-based medicine is limited regarding the efficacy and safety of immunotherapy in elderly patients aged 75 years and older with malignant solid tumors. PRaG therapy, which combines PD-1/PD-L1 inhibitors, radiotherapy, and granulocyte-macrophage colony-stimulating factor (GM-CSF), aims to treat patients with advanced, refractory tumors. Preliminary findings indicate that patients aged 75 years and older can benefit from this treatment and can tolerate it well. <b>Objective:</b> This study aims to evaluate the efficacy and safety of the PRaG regimen in elderly patients with advanced malignant solid tumors to provide evidence-based support for immunotherapy in this population. <b>Methods and Analysis:</b> This study involves a multicenter, prospective, single-arm phase II clinical trial designed to enroll 29 patients aged 75 years and older with either newly diagnosed or recurrent metastatic advanced solid tumors that are histologically confirmed. All of the eligible patients will have had to receive at least two cycles of PRaG therapy until disease progression or intolerable adverse effects occurred. The study protocol was approved on September 12, 2023, by the Ethics Committee of the Second Affiliated Hospital of Soochow University (JD-LK-2023-082-I01) and by the ethics committees of all of the participating centers (Trial Registration Number: NCT06112041).</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251400412"},"PeriodicalIF":2.8,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12660646/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145639407","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Study on Synchronous Bilateral Breast Cancer Radiotherapy Based on an Accelerator Integrated with Optical Surface Monitoring System. 基于光学表面监测系统加速器的双侧乳腺癌同步放疗研究。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 DOI: 10.1177/15330338251322075
Zhen Zhou, Tingting Dong, Bei Wang, Zhiqun Wang, Heling Zhu, Wenbo Li, Bo Yang, Jie Qiu

Objective: To investigate the optimal radiotherapy regimen for synchronous bilateral breast cancer (SBBC) by utilizing dosimetric and radiobiological indicators, and to assess the impact of applying an optical surface monitoring system(OSMS) on the precision of SBBC radiotherapy treatment.

Methods: Nine patients with SBBC who underwent breast-conserving radiotherapy were retrospectively selected. Four treatment plans were designed for each patient using the Versa HD (Elekta, Stockholm) accelerator: single-isocenter intensity-modulated radiotherapy/volumetric modulated arc therapy(IMRT-ISO1/VMAT-ISO1) and dual-isocenter IMRT/VMAT(IMRT-ISO2/VMAT-ISO2), with a prescription dose of 42.4 Gy in 16 fractions. Dosimetric parameters and radiobiological impact were measured for the target and organs at risk(OARs). The monitoring log files of three SBBC patients were analyzed to quantitatively assess real-time delta shifts encompassing six degrees of freedom (DOFs) during intrafraction and interfraction treatment processes.

Results: Compared to both the IMRT techniques, the VMAT techniques offered superior target conformity, uniformity, and dose fall-off capability. Among the four treatment plans, VMAT-ISO1 exhibited optimal performance by significantly reducing radiation exposure volume to OARs while maintaining exceptional precision in dose delivery and execution efficiency. The tumor control probability (TCP) was exceeded by 98.5% for all four modalities. According to the OSMS logs, the maximum absolute error in translational motion during the treatment of three SBBC patients was predominantly manifested along the vertical(VRT) axis, with an mean value of 2.2 mm. Additionally, it was observed that the coronal plane (YAW) exhibited the largest error in terms of rotational angle, with an mean deviation of 1.1°.

Conclusions: The VMAT-ISO1 technique demonstrates apparent dosimetric and radiobiological advantages in SBBC radiotherapy, ensuring precise dose delivery and shortening treatment durations. The accuracy of SBBC radiotherapy is ensured by OSMS through pre-treatment positioning correction and real-time monitoring throughout the treatment process.

目的:应用剂量学和放射生物学指标探讨同步双侧乳腺癌(SBBC)的最佳放疗方案,并评价应用光学表面监测系统(OSMS)对同步双侧乳腺癌放疗精度的影响。方法:回顾性分析9例行保乳放疗的SBBC患者。使用Versa HD (Elekta, Stockholm)加速器为每位患者设计了四种治疗方案:单等中心调强放疗/体积调弧治疗(IMRT- iso1 /VMAT- iso1)和双等中心IMRT/VMAT(IMRT- iso2 /VMAT- iso2),处方剂量为42.4 Gy,分16份。测量靶和危险器官(OARs)的剂量学参数和放射生物学影响。分析3例SBBC患者的监测日志文件,定量评估在抽吸和干涉治疗过程中包含6个自由度(dfs)的实时delta位移。结果:与两种IMRT技术相比,VMAT技术具有更好的靶一致性、均匀性和剂量衰减能力。在四种治疗方案中,VMAT-ISO1表现出最佳的性能,显着减少了OARs的辐射暴露量,同时保持了出色的剂量传递精度和执行效率。四种方式的肿瘤控制概率(TCP)均超过98.5%。根据OSMS日志,3例SBBC患者在治疗过程中,平移运动的最大绝对误差主要表现在垂直(VRT)轴上,平均值为2.2 mm。此外,观察到冠状面(YAW)在旋转角度方面的误差最大,平均偏差为1.1°。结论:VMAT-ISO1技术在SBBC放射治疗中具有明显的剂量学和放射生物学优势,确保了精确的剂量传递和缩短治疗时间。OSMS通过治疗前定位校正和整个治疗过程的实时监测,确保SBBC放疗的准确性。
{"title":"A Study on Synchronous Bilateral Breast Cancer Radiotherapy Based on an Accelerator Integrated with Optical Surface Monitoring System.","authors":"Zhen Zhou, Tingting Dong, Bei Wang, Zhiqun Wang, Heling Zhu, Wenbo Li, Bo Yang, Jie Qiu","doi":"10.1177/15330338251322075","DOIUrl":"10.1177/15330338251322075","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the optimal radiotherapy regimen for synchronous bilateral breast cancer (SBBC) by utilizing dosimetric and radiobiological indicators, and to assess the impact of applying an optical surface monitoring system(OSMS) on the precision of SBBC radiotherapy treatment.</p><p><strong>Methods: </strong>Nine patients with SBBC who underwent breast-conserving radiotherapy were retrospectively selected. Four treatment plans were designed for each patient using the Versa HD (Elekta, Stockholm) accelerator: single-isocenter intensity-modulated radiotherapy/volumetric modulated arc therapy(IMRT-ISO1/VMAT-ISO1) and dual-isocenter IMRT/VMAT(IMRT-ISO2/VMAT-ISO2), with a prescription dose of 42.4 Gy in 16 fractions. Dosimetric parameters and radiobiological impact were measured for the target and organs at risk(OARs). The monitoring log files of three SBBC patients were analyzed to quantitatively assess real-time delta shifts encompassing six degrees of freedom (DOFs) during intrafraction and interfraction treatment processes.</p><p><strong>Results: </strong>Compared to both the IMRT techniques, the VMAT techniques offered superior target conformity, uniformity, and dose fall-off capability. Among the four treatment plans, VMAT-ISO1 exhibited optimal performance by significantly reducing radiation exposure volume to OARs while maintaining exceptional precision in dose delivery and execution efficiency. The tumor control probability (TCP) was exceeded by 98.5% for all four modalities. According to the OSMS logs, the maximum absolute error in translational motion during the treatment of three SBBC patients was predominantly manifested along the vertical(VRT) axis, with an mean value of 2.2 mm. Additionally, it was observed that the coronal plane (YAW) exhibited the largest error in terms of rotational angle, with an mean deviation of 1.1°.</p><p><strong>Conclusions: </strong>The VMAT-ISO1 technique demonstrates apparent dosimetric and radiobiological advantages in SBBC radiotherapy, ensuring precise dose delivery and shortening treatment durations. The accuracy of SBBC radiotherapy is ensured by OSMS through pre-treatment positioning correction and real-time monitoring throughout the treatment process.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251322075"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11848896/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143484066","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Attention-based Vision Transformer Enables Early Detection of Radiotherapy-Induced Toxicity in Magnetic Resonance Images of a Preclinical Model. 基于注意力的视觉转换器能够在临床前模型的磁共振图像中早期检测放射治疗引起的毒性。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-04-04 DOI: 10.1177/15330338251333018
Manish Kakar, Bao Ngoc Huynh, Olga Zlygosteva, Inga Solgård Juvkam, Nina Edin, Oliver Tomic, Cecilia Marie Futsaether, Eirik Malinen

IntroductionEarly identification of patients at risk for toxicity induced by radiotherapy (RT) is essential for developing personalized treatments and mitigation plans. Preclinical models with relevant endpoints are critical for systematic evaluation of normal tissue responses. This study aims to determine whether attention-based vision transformers can classify MR images of irradiated and control mice, potentially aiding early identification of individuals at risk of developing toxicity.MethodC57BL/6J mice (n = 14) were subjected to 66 Gy of fractionated RT targeting the oral cavity, swallowing muscles, and salivary glands. A control group (n = 15) received no irradiation but was otherwise treated identically. T2-weighted MR images were obtained 3-5 days post-irradiation. Late toxicity in terms of saliva production in individual mice was assessed at day 105 after treatment. A pre-trained vision transformer model (ViT Base 16) was employed to classify the images into control and irradiated groups.ResultsThe ViT Base 16 model classified the MR images with an accuracy of 69%, with identical overall performance for control and irradiated animals. The ViT's model predictions showed a significant correlation with late toxicity (r = 0.65, p < 0.01). One of the attention maps from the ViT model highlighted the irradiated regions of the animals.ConclusionsAttention-based vision transformers using MRI have the potential to predict individuals at risk of developing early toxicity. This approach may enhance personalized treatment and follow-up strategies in head and neck cancer radiotherapy.

早期识别有放射治疗(RT)毒性风险的患者对于制定个性化治疗和缓解计划至关重要。具有相关终点的临床前模型对于系统评估正常组织反应至关重要。这项研究的目的是确定基于注意力的视觉转换器是否可以对辐射小鼠和对照小鼠的MR图像进行分类,从而潜在地帮助早期识别具有毒性风险的个体。方法c57bl /6J小鼠(n = 14)以口腔、吞咽肌和唾液腺为靶点,接受66 Gy的分级放射治疗。对照组(n = 15)不接受放射治疗,其他治疗方法相同。照射后3-5天获得t2加权MR图像。在治疗后第105天,对个体小鼠唾液产生的晚期毒性进行了评估。使用预训练的视觉转换模型(ViT Base 16)将图像分为对照组和辐照组。结果ViT Base 16模型对MR图像的分类准确率为69%,在对照组和辐照动物中具有相同的总体性能。ViT模型预测与晚期毒性显著相关(r = 0.65, p
{"title":"Attention-based Vision Transformer Enables Early Detection of Radiotherapy-Induced Toxicity in Magnetic Resonance Images of a Preclinical Model.","authors":"Manish Kakar, Bao Ngoc Huynh, Olga Zlygosteva, Inga Solgård Juvkam, Nina Edin, Oliver Tomic, Cecilia Marie Futsaether, Eirik Malinen","doi":"10.1177/15330338251333018","DOIUrl":"10.1177/15330338251333018","url":null,"abstract":"<p><p>IntroductionEarly identification of patients at risk for toxicity induced by radiotherapy (RT) is essential for developing personalized treatments and mitigation plans. Preclinical models with relevant endpoints are critical for systematic evaluation of normal tissue responses. This study aims to determine whether attention-based vision transformers can classify MR images of irradiated and control mice, potentially aiding early identification of individuals at risk of developing toxicity.MethodC57BL/6J mice (n = 14) were subjected to 66 Gy of fractionated RT targeting the oral cavity, swallowing muscles, and salivary glands. A control group (n = 15) received no irradiation but was otherwise treated identically. T2-weighted MR images were obtained 3-5 days post-irradiation. Late toxicity in terms of saliva production in individual mice was assessed at day 105 after treatment. A pre-trained vision transformer model (ViT Base 16) was employed to classify the images into control and irradiated groups.ResultsThe ViT Base 16 model classified the MR images with an accuracy of 69%, with identical overall performance for control and irradiated animals. The ViT's model predictions showed a significant correlation with late toxicity (r = 0.65, p < 0.01). One of the attention maps from the ViT model highlighted the irradiated regions of the animals.ConclusionsAttention-based vision transformers using MRI have the potential to predict individuals at risk of developing early toxicity. This approach may enhance personalized treatment and follow-up strategies in head and neck cancer radiotherapy.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251333018"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11970093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143781166","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Treatment Outcome of Brain Metastases from Breast Cancer Following Gamma Knife Radiosurgery: A Retrospective Study in Vietnam. 伽玛刀放射外科手术后乳腺癌脑转移的治疗效果:越南的一项回顾性研究
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-03-17 DOI: 10.1177/15330338251328522
Huyen Thi Phung, Yen Thi Le, Tung Van Nguyen, Giang Tien Dang, Quang Hong Nguyen, Duong Thanh Phan, Hoa Thi Nguyen, Long Thanh Nguyen

BackgroundGamma Knife radiosurgery has proven to be highly effective for small brain lesions and those with a limited number of metastases. This study aimed to evaluate the treatment outcome of Gamma Knife radiosurgery in Vietnamese breast cancer patients with brain metastasis.MethodsThis retrospective descriptive study included 75 patients treated between January 2019 and December 2023. Eligible patients had 1 to 5 brain lesions ≤ 3 cm, a Karnofsky Performance Status (KPS) score of ≥ 60, and no prior whole-brain radiotherapy or brain tumor resection. Clinical characteristics were documented, and imaging responses were evaluated using RECIST criteria. Overall survival (OS), brain-specific progression-free survival (BSPFS), and overall response rates were analyzed using Kaplan-Meier survival curves and Cox regression.ResultsSeventy-five patients were included in the study, with a median follow-up time of 15.9 months. The median age was 53.0 years (range: 29-73 years), and 39 patients (52%) were HER2-positive. The median total tumor volume per patient was 3.78 cm3. A total of 152 brain tumors were identified, of which 131 (86.2%) were <2 cm in diameter, 36 patients (48.0%) had a single lesion. The intracranial tumor control rates were 96% at 3 months and 92.5% at 6 months. The median overall survival (OS) was 17.2 months (range: 13.7-20.7 months). Multivariate analysis revealed that the total volume of metastatic lesions ≤7.0 cm3, hormone receptor negativity, ≤ 3 lines of systemic treatment before brain metastasis and controlled extracranial metastases were correlated with both BSPFS and OS.ConclusionGamma Knife radiosurgery is an effective treatment for limited brain metastases, demonstrating a high rate of local control over brain lesions, which contributed to the promising survival outcome in Vietnamese breast cancer patients.

背景伽玛刀放射手术已被证明对小脑病变和转移数量有限的脑病变非常有效。本研究旨在评估伽玛刀放射治疗越南乳腺癌脑转移患者的治疗效果。方法本回顾性描述性研究纳入2019年1月至2023年12月期间接受治疗的75例患者。符合条件的患者有1 ~ 5个≤3cm的脑病变,Karnofsky Performance Status (KPS)评分≥60,既往无全脑放疗或脑肿瘤切除术。记录临床特征,并使用RECIST标准评估影像学反应。采用Kaplan-Meier生存曲线和Cox回归分析总生存期(OS)、脑特异性无进展生存期(BSPFS)和总有效率。结果75例患者纳入研究,中位随访时间15.9个月。中位年龄为53.0岁(范围29-73岁),39例(52%)患者为her2阳性。每位患者肿瘤总体积中位数为3.78 cm3。共鉴定出152例脑肿瘤,其中3例131例(86.2%),激素受体阴性、脑转移前系统性治疗≤3线及控制性颅外转移均与BSPFS和OS相关。结论伽玛刀放射治疗有限脑转移灶是一种有效的治疗方法,对脑病变有很高的局部控制率,这有助于越南乳腺癌患者的生存结果。
{"title":"Treatment Outcome of Brain Metastases from Breast Cancer Following Gamma Knife Radiosurgery: A Retrospective Study in Vietnam.","authors":"Huyen Thi Phung, Yen Thi Le, Tung Van Nguyen, Giang Tien Dang, Quang Hong Nguyen, Duong Thanh Phan, Hoa Thi Nguyen, Long Thanh Nguyen","doi":"10.1177/15330338251328522","DOIUrl":"10.1177/15330338251328522","url":null,"abstract":"<p><p>BackgroundGamma Knife radiosurgery has proven to be highly effective for small brain lesions and those with a limited number of metastases. This study aimed to evaluate the treatment outcome of Gamma Knife radiosurgery in Vietnamese breast cancer patients with brain metastasis.MethodsThis retrospective descriptive study included 75 patients treated between January 2019 and December 2023. Eligible patients had 1 to 5 brain lesions ≤ 3 cm, a Karnofsky Performance Status (KPS) score of ≥ 60, and no prior whole-brain radiotherapy or brain tumor resection. Clinical characteristics were documented, and imaging responses were evaluated using RECIST criteria. Overall survival (OS), brain-specific progression-free survival (BSPFS), and overall response rates were analyzed using Kaplan-Meier survival curves and Cox regression.ResultsSeventy-five patients were included in the study, with a median follow-up time of 15.9 months. The median age was 53.0 years (range: 29-73 years), and 39 patients (52%) were HER2-positive. The median total tumor volume per patient was 3.78 cm<sup>3</sup>. A total of 152 brain tumors were identified, of which 131 (86.2%) were <2 cm in diameter, 36 patients (48.0%) had a single lesion. The intracranial tumor control rates were 96% at 3 months and 92.5% at 6 months. The median overall survival (OS) was 17.2 months (range: 13.7-20.7 months). Multivariate analysis revealed that the total volume of metastatic lesions ≤7.0 cm<sup>3</sup>, hormone receptor negativity, ≤ 3 lines of systemic treatment before brain metastasis and controlled extracranial metastases were correlated with both BSPFS and OS.ConclusionGamma Knife radiosurgery is an effective treatment for limited brain metastases, demonstrating a high rate of local control over brain lesions, which contributed to the promising survival outcome in Vietnamese breast cancer patients.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251328522"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11915535/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143650927","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Dosimetric and Radiobiological Impact of Patient Setup Errors in Intensity-modulated Radiotherapy for Esophageal Cancer. 食管癌调强放疗中患者设置错误对剂量学和放射生物学的影响。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 DOI: 10.1177/15330338241311136
Jia-Huan Cai, Xun Peng, Jia-Yang Lu

Purpose: To evaluate the impact of patient setup errors on the dosimetry and radiobiological models of intensity-modulated radiotherapy (IMRT) for esophageal cancer.

Methods and materials: This retrospective study with 56 patients in thermoplastic mask (TM) and vacuum bag (VB) groups utilized real setup-error (RSE) data from cone-beam CT scans to generate simulated setup-error (SSE) data following a normal distribution. The SSE data were applied to simulate all treatment fractions per patient by shifting the plan isocenter and recalculating the dose. A simulated plan sum (SPS) was created by accumulating all simulated fraction plans. Comparisons of target dose, improved homogeneity index (iHI), conformity index (CI), tumor control probability (TCP) and normal tissue complication probability (NTCP) were conducted between SPSs and original treatment plans (OTPs). Correlations between RSE and TCP/NTCP were analyzed.

Results: Compared to OTPs in the TM group, the planning target volume (PTV) of SPSs showed reductions in D95%, D98%, iHI, CI and TCP by 1.2%, 2.2%, 2.3%, 7.3% and 1.2%, while D2% increased by 0.3%; D2% of clinical target volume (CTV) increased by 0.2% (P < .05). In the VB group, D95%, D98%, iHI, CI and TCP of PTV decreased by 2.5%, 4.5%, 4.2%, 15.6% and 2.0%, with D2% increasing by 0.5%; D2% of CTV increased by 0.5% while D98% decreased by 0.2% (P < .05). The dose of organs at risk (OARs) changed slightly in both groups. The mean and standard deviation of absolute RSE negatively correlated with the TCP of PTV, while the mean RSE positively correlated with the NTCP of lung and spinal cord.

Conclusions: Setup errors may reduce dose homogeneity and conformity, potentially reducing TCP of PTV and increasing NTCP, especially when mean RSE shifts the isocenter towards OARs. VB immobilization may result in relatively larger impacts of setup errors, but this needs future validation.

目的:评价患者设置错误对食管癌调强放疗剂量学和放射生物学模型的影响。方法和材料:本回顾性研究采用热塑性口罩(TM)组和真空袋(VB)组56例患者,利用锥束CT扫描的真实设置误差(RSE)数据生成符合正态分布的模拟设置误差(SSE)数据。SSE数据通过移动计划等中心和重新计算剂量来模拟每个患者的所有治疗分数。将所有模拟分数方案累加形成模拟方案和(SPS)。比较SPSs与原治疗方案(OTPs)的靶剂量、改善均匀性指数(iHI)、符合性指数(CI)、肿瘤控制概率(TCP)和正常组织并发症概率(NTCP)。分析RSE与TCP/NTCP的相关性。结果:与TM组相比,sp的计划靶体积(PTV) D95%、D98%、iHI、CI和TCP分别降低1.2%、2.2%、2.3%、7.3%和1.2%,D2%升高0.3%;临床靶体积(CTV)的D2%升高0.2% (P分别为95%、98%,PTV的iHI、CI、TCP分别降低2.5%、4.5%、4.2%、15.6%、2.0%,D2%升高0.5%;结论:设置误差可能降低剂量均匀性和一致性,可能降低PTV的TCP并增加NTCP,特别是当平均RSE使等中心向OARs移动时。VB固定可能会导致相对较大的设置错误影响,但这需要进一步验证。
{"title":"Dosimetric and Radiobiological Impact of Patient Setup Errors in Intensity-modulated Radiotherapy for Esophageal Cancer.","authors":"Jia-Huan Cai, Xun Peng, Jia-Yang Lu","doi":"10.1177/15330338241311136","DOIUrl":"10.1177/15330338241311136","url":null,"abstract":"<p><strong>Purpose: </strong>To evaluate the impact of patient setup errors on the dosimetry and radiobiological models of intensity-modulated radiotherapy (IMRT) for esophageal cancer.</p><p><strong>Methods and materials: </strong>This retrospective study with 56 patients in thermoplastic mask (TM) and vacuum bag (VB) groups utilized real setup-error (RSE) data from cone-beam CT scans to generate simulated setup-error (SSE) data following a normal distribution. The SSE data were applied to simulate all treatment fractions per patient by shifting the plan isocenter and recalculating the dose. A simulated plan sum (SPS) was created by accumulating all simulated fraction plans. Comparisons of target dose, improved homogeneity index (iHI), conformity index (CI), tumor control probability (TCP) and normal tissue complication probability (NTCP) were conducted between SPSs and original treatment plans (OTPs). Correlations between RSE and TCP/NTCP were analyzed.</p><p><strong>Results: </strong>Compared to OTPs in the TM group, the planning target volume (PTV) of SPSs showed reductions in D<sub>95%</sub>, D<sub>98%</sub>, iHI, CI and TCP by 1.2%, 2.2%, 2.3%, 7.3% and 1.2%, while D<sub>2%</sub> increased by 0.3%; D<sub>2%</sub> of clinical target volume (CTV) increased by 0.2% (<i>P </i>< .05). In the VB group, D<sub>95%</sub>, D<sub>98%</sub>, iHI, CI and TCP of PTV decreased by 2.5%, 4.5%, 4.2%, 15.6% and 2.0%, with D<sub>2%</sub> increasing by 0.5%; D<sub>2%</sub> of CTV increased by 0.5% while D<sub>98%</sub> decreased by 0.2% (<i>P </i>< .05). The dose of organs at risk (OARs) changed slightly in both groups. The mean and standard deviation of absolute RSE negatively correlated with the TCP of PTV, while the mean RSE positively correlated with the NTCP of lung and spinal cord.</p><p><strong>Conclusions: </strong>Setup errors may reduce dose homogeneity and conformity, potentially reducing TCP of PTV and increasing NTCP, especially when mean RSE shifts the isocenter towards OARs. VB immobilization may result in relatively larger impacts of setup errors, but this needs future validation.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338241311136"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11755542/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143012180","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
An Ultrasound-based Machine Learning Model for Predicting Tumor-Infiltrating Lymphocytes in Breast Cancer. 基于超声的机器学习模型预测乳腺癌肿瘤浸润淋巴细胞。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-04-17 DOI: 10.1177/15330338251334453
Boya Liu, Xiangrong Gu, Danling Xie, Bing Zhao, Dong Han, Yuli Zhang, Tao Li, Jingqin Fang

IntroductionTumor-infiltrating lymphocytes (TILs) are key indicators of immune response and prognosis in breast cancer (BC). Accurate prediction of TIL levels is essential for guiding personalized treatment strategies. This study aimed to develop and evaluate machine learning models using ultrasound-derived radiomics and clinical features to predict TIL levels in BC.MethodsThis retrospective study included 256 BC patients between January 2019 and August 2023, who were randomly divided into training (n = 179) and test (n = 77) cohorts. Radiomics features were extracted from the intratumor and peritumor regions in ultrasound images. Feature selection was performed using the "Boruta" package in R to iteratively remove non-significant features. Extra Trees Classifier was used to construct radiomics and clinical models. A combined radiomics-clinical (R-C) model was also developed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and decision curve analysis (DCA) to assess clinical utility. A nomogram was created based on the best-performing model.ResultsA total of 1712 radiomics features were extracted from the intratumor and peritumor regions. The Boruta method selected five key features (four from the peritumor and one from the intratumor) for model construction. Clinical features, including immunohistochemistry, tumor size, shape, and echo characteristics, showed significant differences between high (≥10%) and low (<10%) TIL groups. Both the R-C and radiomics models outperformed the clinical model in the test cohort (area under the curve values of 0.869/0.838 vs 0.627, P < .05). Calibration curves and Brier scores demonstrated superior accuracy and calibration for the R-C and radiomics models. DCA revealed the highest net benefit of the R-C model at intermediate threshold probabilities.ConclusionUltrasound-derived radiomics effectively predicts TIL levels in BC, providing valuable insights for personalized treatment and surveillance strategies.

肿瘤浸润淋巴细胞(til)是乳腺癌(BC)免疫反应和预后的关键指标。准确预测TIL水平对于指导个性化治疗策略至关重要。本研究旨在利用超声衍生放射组学和临床特征开发和评估机器学习模型,以预测BC中的TIL水平。方法回顾性研究纳入2019年1月至2023年8月期间的256例BC患者,随机分为训练组(n = 179)和检验组(n = 77)。从超声图像中提取肿瘤内和肿瘤周围区域的放射组学特征。使用R中的“Boruta”包进行特征选择,迭代地删除不重要的特征。Extra Trees Classifier用于构建放射组学和临床模型。同时建立了放射组学-临床(R-C)联合模型。采用受试者工作特征曲线下面积(AUC)、准确性、敏感性、特异性和决策曲线分析(DCA)来评估模型的临床应用。基于最佳表现模型创建了一个nomogram。结果从肿瘤内和肿瘤周围共提取了1712个放射组学特征。Boruta方法选取5个关键特征(4个来自肿瘤周围,1个来自肿瘤内部)进行模型构建。临床特征,包括免疫组织化学、肿瘤大小、形状和回声特征,在高(≥10%)和低(P
{"title":"An Ultrasound-based Machine Learning Model for Predicting Tumor-Infiltrating Lymphocytes in Breast Cancer.","authors":"Boya Liu, Xiangrong Gu, Danling Xie, Bing Zhao, Dong Han, Yuli Zhang, Tao Li, Jingqin Fang","doi":"10.1177/15330338251334453","DOIUrl":"https://doi.org/10.1177/15330338251334453","url":null,"abstract":"<p><p>IntroductionTumor-infiltrating lymphocytes (TILs) are key indicators of immune response and prognosis in breast cancer (BC). Accurate prediction of TIL levels is essential for guiding personalized treatment strategies. This study aimed to develop and evaluate machine learning models using ultrasound-derived radiomics and clinical features to predict TIL levels in BC.MethodsThis retrospective study included 256 BC patients between January 2019 and August 2023, who were randomly divided into training (n = 179) and test (n = 77) cohorts. Radiomics features were extracted from the intratumor and peritumor regions in ultrasound images. Feature selection was performed using the \"Boruta\" package in R to iteratively remove non-significant features. Extra Trees Classifier was used to construct radiomics and clinical models. A combined radiomics-clinical (R-C) model was also developed. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC), accuracy, sensitivity, specificity, and decision curve analysis (DCA) to assess clinical utility. A nomogram was created based on the best-performing model.ResultsA total of 1712 radiomics features were extracted from the intratumor and peritumor regions. The Boruta method selected five key features (four from the peritumor and one from the intratumor) for model construction. Clinical features, including immunohistochemistry, tumor size, shape, and echo characteristics, showed significant differences between high (≥10%) and low (<10%) TIL groups. Both the R-C and radiomics models outperformed the clinical model in the test cohort (area under the curve values of 0.869/0.838 vs 0.627, <i>P</i> < .05). Calibration curves and Brier scores demonstrated superior accuracy and calibration for the R-C and radiomics models. DCA revealed the highest net benefit of the R-C model at intermediate threshold probabilities.ConclusionUltrasound-derived radiomics effectively predicts TIL levels in BC, providing valuable insights for personalized treatment and surveillance strategies.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251334453"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12035158/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143987615","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Retrospective Insights into the Clinicopathological Features and Treatment Outcomes of Thoracic SMARCA4-Deficient Tumors. 胸部smarca4缺陷肿瘤的临床病理特征及治疗结果的回顾性分析
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-05-22 DOI: 10.1177/15330338251345377
Lijin Chen, Chunyang Su, Jiadi Yao, Xiaofeng Li, Xiaoyan Lin

IntroductionThoracic SMARCA4-deficient tumors, which are rare and aggressive malignancies found in the lung or thoracic cavity, present a challenge in treatment standardization. This challenge arises from their resistance to chemotherapy and the absence of targeted therapy options.MethodsThoracic SMARCA4-deficient tumors were identified retrospectively using pathology databases. The clinicopathological characteristics of these tumors are outlined, and the clinical outcomes of advanced patients treated with immune checkpoint inhibitors (ICIs) in combination with chemotherapy and chemotherapy alone are reviewed.ResultsThirty-nine patients had thoracic SMARCA4-deficient tumors, with a median age of 62 years. The cohort consisted of 92.3% males, and 89.7% had a history of smoking. Within this group, 94.9% had stage III/IV disease at diagnosis. SMARCA4-deficient non-small cell lung cancer (SMARCA4-DNSCLC) and SMARCA4-deficient undifferentiated tumors (SMARCA4-DUT) display distinct histological and immunohistochemical features. Thirty-five patients underwent systemic therapy, achieving an ORR of 51.4%, a DCR of 82.9%, and a median OS of 20.9 months. Patients were categorized into chemotherapy (28.6%) and ICIs plus chemotherapy (71.4%) groups. The ICIs plus chemotherapy group exhibited an ORR of 64.0% and a DCR of 96.0%, while the chemotherapy group had an ORR of 20.0% and 50.0%, respectively (P < .0001 for ORR and DCR). The median OS for ICIs plus chemotherapy and chemotherapy groups were 20.9 months and 6.5 months, and median PFS were 9.6 months and 3.5 months, respectively, all statistically significant (P < .05). Multivariate COX regression analysis indicated that treatment was an independent prognostic factor for OS.ConclusionThoracic SMARCA4-deficient tumors exhibit a lack of SMARCA4 expression, displaying high malignancy and aggressiveness while exhibiting poor response to standard chemotherapy. The combination of ICIs with chemotherapy could potentially serve as an effective treatment approach for thoracic SMARCA4-deficient tumors.

胸腔smarca4缺陷肿瘤是一种罕见的侵袭性恶性肿瘤,多发于肺或胸腔,对规范化治疗提出了挑战。这一挑战源于他们对化疗的耐药性和缺乏靶向治疗方案。方法回顾性分析胸椎smarca4缺陷肿瘤。本文概述了这些肿瘤的临床病理特征,并综述了晚期患者使用免疫检查点抑制剂(ICIs)联合化疗和单独化疗的临床结果。结果39例患者患有胸椎smarca4缺陷肿瘤,中位年龄为62岁。该队列由92.3%的男性组成,89.7%的人有吸烟史。在该组中,94.9%在诊断时为III/IV期疾病。smarca4缺陷的非小细胞肺癌(SMARCA4-DNSCLC)和smarca4缺陷的未分化肿瘤(SMARCA4-DUT)表现出不同的组织学和免疫组织化学特征。35例患者接受了全身治疗,ORR为51.4%,DCR为82.9%,中位OS为20.9个月。患者分为化疗组(28.6%)和ICIs +化疗组(71.4%)。ICIs +化疗组ORR为64.0%,DCR为96.0%,化疗组ORR分别为20.0%和50.0% (P < 0.05)
{"title":"Retrospective Insights into the Clinicopathological Features and Treatment Outcomes of Thoracic SMARCA4-Deficient Tumors.","authors":"Lijin Chen, Chunyang Su, Jiadi Yao, Xiaofeng Li, Xiaoyan Lin","doi":"10.1177/15330338251345377","DOIUrl":"10.1177/15330338251345377","url":null,"abstract":"<p><p>IntroductionThoracic SMARCA4-deficient tumors, which are rare and aggressive malignancies found in the lung or thoracic cavity, present a challenge in treatment standardization. This challenge arises from their resistance to chemotherapy and the absence of targeted therapy options.MethodsThoracic SMARCA4-deficient tumors were identified retrospectively using pathology databases. The clinicopathological characteristics of these tumors are outlined, and the clinical outcomes of advanced patients treated with immune checkpoint inhibitors (ICIs) in combination with chemotherapy and chemotherapy alone are reviewed.ResultsThirty-nine patients had thoracic SMARCA4-deficient tumors, with a median age of 62 years. The cohort consisted of 92.3% males, and 89.7% had a history of smoking. Within this group, 94.9% had stage III/IV disease at diagnosis. SMARCA4-deficient non-small cell lung cancer (SMARCA4-DNSCLC) and SMARCA4-deficient undifferentiated tumors (SMARCA4-DUT) display distinct histological and immunohistochemical features. Thirty-five patients underwent systemic therapy, achieving an ORR of 51.4%, a DCR of 82.9%, and a median OS of 20.9 months. Patients were categorized into chemotherapy (28.6%) and ICIs plus chemotherapy (71.4%) groups. The ICIs plus chemotherapy group exhibited an ORR of 64.0% and a DCR of 96.0%, while the chemotherapy group had an ORR of 20.0% and 50.0%, respectively (<i>P</i> < .0001 for ORR and DCR). The median OS for ICIs plus chemotherapy and chemotherapy groups were 20.9 months and 6.5 months, and median PFS were 9.6 months and 3.5 months, respectively, all statistically significant (<i>P</i> < .05). Multivariate COX regression analysis indicated that treatment was an independent prognostic factor for OS.ConclusionThoracic SMARCA4-deficient tumors exhibit a lack of SMARCA4 expression, displaying high malignancy and aggressiveness while exhibiting poor response to standard chemotherapy. The combination of ICIs with chemotherapy could potentially serve as an effective treatment approach for thoracic SMARCA4-deficient tumors.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251345377"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099105/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120202","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Streamlining Thoracic Radiotherapy Quality assurance: One-Class Classification for Automated OAR Contour Assessment. 简化胸部放射治疗质量保证:自动OAR轮廓评估的一级分类。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-05-22 DOI: 10.1177/15330338251345895
Yihao Zhao, Cuiyun Yuan, Ying Liang, Yang Li, Chunxia Li, Man Zhao, Jun Hu, Ningze Zhong, Wei Liu, Chenbin Liu

PurposeAutomating quality assurance (QA) for contours generated by automatic algorithms is critical in radiotherapy treatment planning. Manual QA is tedious, time-consuming, and prone to subjective experiences. Automatic segmentation reduces physician workload and improves consistency. However, an effective QA process for these automatic contours remains an unmet need in clinical practice.Materials and MethodsThe patient data used in this study was derived from the AAPM Thoracic Auto-Segmentation Challenge dataset, including left and right lungs, heart, esophagus, and spinal cord. Two groups of organ-at-risk (OAR) were generated. A ResNet-152 network was used as a feature extractor, and a one-class support vector machine (OC-SVM) was employed to classify contours as 'high' or 'low' quality. To evaluate the generalizability, we generated low-quality contours using translation and resizing techniques and assessed correlations between detection limits and metrics such as volume, Dice similarity coefficient (DSC), 95% Hausdorff distance (HD95), and mean surface distance (MSD).ResultsThe proposed OC-SVM model outperformed binary classifiers n metrics such as balanced accuracy and area under the receiver operating characteristic curve (AUC) . It demonstrated superior performance in detecting various types of contour errors while maintaining high interpretability. Strong correlations were observed between detection limits and contour metrics.ConclusionOur proposed model integrates an attention mechanism with a one-class classification framework to automate QA for OAR delineations. This approach effectively detects diverse types of contour errors with high accuracy, significantly reducing the burden on physicians during radiotherapy planning.

目的对自动算法生成的轮廓线进行自动质量保证(QA)是放疗治疗计划的关键。手动QA是乏味的,耗时的,并且倾向于主观体验。自动分割减少了医生的工作量,提高了一致性。然而,在临床实践中,这些自动轮廓的有效QA过程仍然是一个未满足的需求。材料和方法本研究中使用的患者数据来自AAPM胸腔自动分割挑战数据集,包括左、右肺、心脏、食道和脊髓。产生两组器官危险组(OAR)。使用ResNet-152网络作为特征提取器,并使用一类支持向量机(OC-SVM)对轮廓进行“高”或“低”质量分类。为了评估可泛化性,我们使用平移和调整大小技术生成了低质量轮廓,并评估了检测限与诸如体积、Dice相似系数(DSC)、95% Hausdorff距离(HD95)和平均表面距离(MSD)等指标之间的相关性。结果OC-SVM模型在平衡精度和接收者工作特征曲线下面积(AUC)等指标上优于二元分类器。它在检测各种类型的轮廓误差方面表现出优异的性能,同时保持了较高的可解释性。检出限与轮廓指标之间存在很强的相关性。我们提出的模型将注意力机制与单类分类框架相结合,实现了对桨叶描述的自动化QA。该方法有效地检测了各种类型的轮廓误差,精度高,大大减轻了医生在放疗计划中的负担。
{"title":"Streamlining Thoracic Radiotherapy Quality assurance: One-Class Classification for Automated OAR Contour Assessment.","authors":"Yihao Zhao, Cuiyun Yuan, Ying Liang, Yang Li, Chunxia Li, Man Zhao, Jun Hu, Ningze Zhong, Wei Liu, Chenbin Liu","doi":"10.1177/15330338251345895","DOIUrl":"10.1177/15330338251345895","url":null,"abstract":"<p><p>PurposeAutomating quality assurance (QA) for contours generated by automatic algorithms is critical in radiotherapy treatment planning. Manual QA is tedious, time-consuming, and prone to subjective experiences. Automatic segmentation reduces physician workload and improves consistency. However, an effective QA process for these automatic contours remains an unmet need in clinical practice.Materials and MethodsThe patient data used in this study was derived from the AAPM Thoracic Auto-Segmentation Challenge dataset, including left and right lungs, heart, esophagus, and spinal cord. Two groups of organ-at-risk (OAR) were generated. A ResNet-152 network was used as a feature extractor, and a one-class support vector machine (OC-SVM) was employed to classify contours as 'high' or 'low' quality. To evaluate the generalizability, we generated low-quality contours using translation and resizing techniques and assessed correlations between detection limits and metrics such as volume, Dice similarity coefficient (DSC), 95% Hausdorff distance (HD95), and mean surface distance (MSD).ResultsThe proposed OC-SVM model outperformed binary classifiers n metrics such as balanced accuracy and area under the receiver operating characteristic curve (AUC) . It demonstrated superior performance in detecting various types of contour errors while maintaining high interpretability. Strong correlations were observed between detection limits and contour metrics.ConclusionOur proposed model integrates an attention mechanism with a one-class classification framework to automate QA for OAR delineations. This approach effectively detects diverse types of contour errors with high accuracy, significantly reducing the burden on physicians during radiotherapy planning.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251345895"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12099094/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144120470","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Feasibility of Radiotherapy Fiducial Marker Tracking via Single-Shot X-ray Acoustic Tomography. 单次x射线声层析成像放射治疗基准标记跟踪的可行性。
IF 2.7 4区 医学 Q3 ONCOLOGY Pub Date : 2025-01-01 Epub Date: 2025-07-02 DOI: 10.1177/15330338251342867
Norman Alexis Cantú-Delgado, Héctor Mauricio Garnica-Garza

Introductionin radiotherapy, fiducial markers improve the accuracy of radiation delivery, and their use has become increasingly important in the treatment of various cancers, particularly those in the prostate and lung. This work aims to determine, via Monte Carlo simulations and numerical ultrasound transport, the feasibility of fiducial marker localization via single-shot x-ray acoustic computed tomography.Methodspatient data from CT scans for two treatment sites, prostate and lung, were used to model the fiducial marker localization process. Monte Carlo simulation was used to calculate the absorbed dose distribution in each patient resulting from the irradiation with a 120 kVp x-ray imaging source, assuming that the dose is imparted in a short pulse. Ultrasound transport through each patient was modeled with the numerical ultrasound transport package k-Wave. For the image reconstruction process, as the exact internal patient structure will not be known at the time of treatment, a homogenous medium with the patient external contour and dimensions was used.ResultsIt is shown that the use of a homogeneous model to approximate the actual patient material composition during the reconstruction process, necessary as the geometry of the internal structures is not known at the time of the treatment, severely degrades the quality of the x-ray acoustic tomography images, but that it is still possible to determine the fiducial marker position with an accuracy of or better than 1 mm. The largest errors are observed for the lung patient when the lung is in an inflated state.Conclusionsit has been shown that single-shot x-ray acoustic tomography can be an effective tool for the tracking and localization of radiotherapy fiducial markers, exhibiting an accuracy of better than 1 mm, despite the poor visual quality of the resultant images.

在放射治疗中,基准标记物提高了放射传递的准确性,它们的使用在治疗各种癌症,特别是前列腺癌和肺癌方面变得越来越重要。这项工作旨在通过蒙特卡罗模拟和数值超声传输来确定通过单次x射线声学计算机断层扫描进行基准标记定位的可行性。方法利用前列腺和肺两个治疗部位的CT扫描数据来模拟基础标记物定位过程。采用蒙特卡罗模拟计算了在短脉冲照射剂量的情况下,在120 kVp x射线成像源照射下,每位患者的吸收剂量分布。通过数值超声传输包k-Wave模拟每个患者的超声传输。在图像重建过程中,由于在治疗时不知道患者的确切内部结构,因此使用具有患者外部轮廓和尺寸的均匀介质。结果表明,在重建过程中使用均匀模型来近似患者的实际材料组成,这是必要的,因为在治疗时不知道内部结构的几何形状,严重降低了x射线声层析成像的质量,但仍然有可能确定基准标记位置,精度为1 mm或更好。当肺部处于充气状态时,观察到最大的误差。结论:单次x线声层析成像是一种有效的放射治疗基准标记物的跟踪和定位工具,尽管所得图像的视觉质量较差,但其精度优于1 mm。
{"title":"Feasibility of Radiotherapy Fiducial Marker Tracking via Single-Shot X-ray Acoustic Tomography.","authors":"Norman Alexis Cantú-Delgado, Héctor Mauricio Garnica-Garza","doi":"10.1177/15330338251342867","DOIUrl":"10.1177/15330338251342867","url":null,"abstract":"<p><p>Introductionin radiotherapy, fiducial markers improve the accuracy of radiation delivery, and their use has become increasingly important in the treatment of various cancers, particularly those in the prostate and lung. This work aims to determine, via Monte Carlo simulations and numerical ultrasound transport, the feasibility of fiducial marker localization via single-shot x-ray acoustic computed tomography.Methodspatient data from CT scans for two treatment sites, prostate and lung, were used to model the fiducial marker localization process. Monte Carlo simulation was used to calculate the absorbed dose distribution in each patient resulting from the irradiation with a 120 kVp x-ray imaging source, assuming that the dose is imparted in a short pulse. Ultrasound transport through each patient was modeled with the numerical ultrasound transport package k-Wave. For the image reconstruction process, as the exact internal patient structure will not be known at the time of treatment, a homogenous medium with the patient external contour and dimensions was used.ResultsIt is shown that the use of a homogeneous model to approximate the actual patient material composition during the reconstruction process, necessary as the geometry of the internal structures is not known at the time of the treatment, severely degrades the quality of the x-ray acoustic tomography images, but that it is still possible to determine the fiducial marker position with an accuracy of or better than 1 mm. The largest errors are observed for the lung patient when the lung is in an inflated state.Conclusionsit has been shown that single-shot x-ray acoustic tomography can be an effective tool for the tracking and localization of radiotherapy fiducial markers, exhibiting an accuracy of better than 1 mm, despite the poor visual quality of the resultant images.</p>","PeriodicalId":22203,"journal":{"name":"Technology in Cancer Research & Treatment","volume":"24 ","pages":"15330338251342867"},"PeriodicalIF":2.7,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12227932/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144554937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Technology in Cancer Research & Treatment
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1